Product Description
Mechanisms of Action: CB1 Antagonist
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: Brazil | Chile | Colombia | European Medicines Agency | Germany | Hungary | India | Ireland | Italy | Peru | Portugal | Slovenia | Sweden | United Kingdom
Approved Indications: None
Known Adverse Events: None
Company: Sanofi
Company Location: PARIS I0 75008
Company CEO: Paul Hudson
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 4: Obesity|Inflammation|Overweight|Insulin Resistance|Healthy Volunteers|Atherosclerosis|Dyslipidemia|Obesity, Abdominal|Other|Alcoholism|Cocaine-Related Disorders|Diabetes, Gestational
Phase 3: Obesity|Type 2 Diabetes|Other|Smoking Cessation|Tobacco Use Disorder|Metabolic Syndrome X|Dyslipidemia|Carotid Stenosis|Coronary Artery Disease|Arteriosclerosis|Albuminuria|Atherosclerosis|Glucose Intolerance|Myocardial Ischemia|Prediabetic State|Weight Loss|Overweight|Stroke|Myocardial Infarction|Obesity, Abdominal|Fatty Liver, Alcoholic|Non-alcoholic Fatty Liver Disease|Prader-Willi Syndrome|Spinal Cord Injuries|Weight Gain|Non-alcoholic Steatohepatitis|Hepatitis, Alcoholic|Schizophrenia
Phase 2: Spinal Cord Injuries|Obesity|Schizophrenia|Marijuana Abuse|Psychotic Disorders|Tobacco Use Disorder|Affective Disorders, Psychotic|Alcoholic Intoxication|Hypertension|Polycystic Ovary Syndrome
Phase 1: Marijuana Abuse
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| 2022-001522-30 | P3 |
Active, not recruiting |
Spinal Cord Injuries |
2024-09-29 |
|
| RIMOFATSCI-2 | P2 |
Unknown status |
Spinal Cord Injuries |
2023-11-01 |
|
| Effec Acomplia gastric sensitivity | P4 |
Completed |
Healthy Volunteers |
2021-03-03 |
|
| RIMOFATSCI-1 | P2 |
Completed |
Spinal Cord Injuries |
2022-06-07 |
|
| 2006-7041-83/hah | N/A |
Not yet recruiting |
Dementia |
2018-11-26 |
|
| 2008-005538-59 | P4 |
Active, not recruiting |
Alcoholism|Cocaine-Related Disorders |
2011-02-18 |
|
| SCCAN | P2 |
Completed |
Marijuana Abuse |
2010-12-28 |
|
| 2008-002500-26 | P3 |
Terminated |
Type 2 Diabetes |
2010-09-08 |
|
| 2008-001015-38 | P3 |
Active, not recruiting |
Schizophrenia |
2010-07-23 |
|
| RIGD | P4 |
Completed |
Diabetes, Gestational|Obesity, Abdominal |
2010-03-16 |
|
| 06-DA-N410 | P1 |
Completed |
Marijuana Abuse |
2010-01-11 |
|
| EFFECTS | P3 |
Terminated |
Type 2 Diabetes|Albuminuria |
2009-07-22 |
|
| CRESCENDO | P3 |
Withdrawn |
Obesity, Abdominal|Stroke |
2009-04-29 |
|
| AUDITOR | P3 |
Terminated |
Arteriosclerosis|Obesity|Carotid Stenosis|Atherosclerosis|Metabolic Syndrome X |
2009-04-01 |
|
| CRESCENDO | P3 |
Terminated |
Myocardial Infarction|Stroke|Obesity, Abdominal |
2009-04-01 |
|
| PRIMARIA | P4 |
Unknown status |
Atherosclerosis |
2009-04-01 |
|
| EC/2006/117/PGMS | P4 |
Terminated |
Obesity |
2009-04-01 |
|
| ALLEGRO | P3 |
Completed |
Overweight |
2009-03-04 |
|
| HP-00041206 | P2 |
Terminated |
Psychotic Disorders|Affective Disorders, Psychotic|Schizophrenia|Obesity|Tobacco Use Disorder|Hypertension |
2009-03-01 |
|
| RAPSODI | P3 |
Terminated |
Glucose Intolerance|Prediabetic State |
2009-03-01 |
|
| STRONG | P3 |
Completed |
Non-alcoholic Steatohepatitis|Hepatitis, Alcoholic |
2009-02-27 |
|
| MODERATO | N/A |
Completed |
Type 2 Diabetes|Dyslipidemia |
2009-02-27 |
|
| TOCCATA | P3 |
Terminated |
Type 2 Diabetes |
2009-02-18 |
|
| EFC10144 | P3 |
Terminated |
Non-alcoholic Fatty Liver Disease|Fatty Liver, Alcoholic |
2009-02-01 |
|
| PRADO | P3 |
Terminated |
Obesity |
2009-02-01 |